Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients With KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02)

Summary

The purpose of this phase I trial is to determine the safety and feasibility of ATP150/ATP152 and VSV-GP154 with or without Ezabenlimab in patients with KRAS G12D/G12V mutated pancreatic adenocarcinoma.

General Information

NCT#: NCT05846516
Study ID: KISIMA-02
Trial Phase: Phase I

Trial Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc., Amal Therapeutics
Therapies Used in This Trial: Ezabenlimab, VSV-GP154, ATP150, ATP152

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search